Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-01
2007-05-01
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S139000
Reexamination Certificate
active
10920738
ABSTRACT:
The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some tetrahydroisoquinoline substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.
REFERENCES:
patent: 5294621 (1994-03-01), Russell
patent: 0 021 580 (1983-12-01), None
patent: 0 076 072 (1987-05-01), None
patent: WO 97/29097 (1997-08-01), None
patent: WO 97/48681 (1997-12-01), None
patent: WO 97/49695 (1997-12-01), None
patent: WO 99/24022 (1999-05-01), None
patent: WO 00/00472 (2000-01-01), None
patent: WO 03/037887 (2003-05-01), None
patent: WO 03/048118 (2003-06-01), None
Yamazaki et al, Chemical Abstracts, vol. 54, Abstracts 28777, 1960.
Vermeulen et al, J. Med. Chem, vol. 47, pp. 5451-5466, Sep. 2004.
Yamazaki et al, vol. 79, pp. 1014-1018, 1960, English Language Translation.
Terron, J. A., IDrugs, vol. 1(3), pp. 302-301, 1998.
Lovenberg et al., Neuron, vol. 11, pp. 449-458, 1993.
Terron, J. A., Br. J. Pharmacol., vol. 121, pp. 563-571, 1997.
Schoeffter et al., Br. J. Pharmacol., vol. 117, pp. 993-994, 1996.
Terron, J. A., Eur. J. Pharmacol., vol. 439, pp. 1-11, 2002.
De Ponti et al., Drugs, vol. 61, pp. 317-332, 2001.
Read et al., Br. J. Pharmacol., vol. 140, pp. 53-60, Jul. 29, 2003.
Wesolowska, A., Polish J. Pharmacol., vol. 54, pp. 327-341, 2002.
Mokrosz et al., J. Med. Chem., vol. 39, pp. 1125-1129, 1996.
Contreras et al., J. Med. Chem., vol. 42, pp. 730-741, 1999.
Alvarez et al., J. Med. Chem., vol. 30, pp. 1186-1193, 1987.
Alvarez et al., Anales Quimica, vol. 80, pp. 283-290, 1984.
Austin et al., Bioorg. Med. Chem. Lett., vol. 9, pp. 179-184, 1999.
Greene et al., Protective Groups in Organic Synthesis, 3rdEd., John Wiley & Sons, Inc., pp. v, xi, xii, 1999.
Mach et al., Bioorg. Med. Chem. Lett., vol. 14(1), pp. 195-202, Jan. 5, 2004.
Munson et al., Anal. Biochem., vol. 107, pp. 220-239, 1980.
Bon et al., J. Org. Chem., vol. 59, pp. 1904-1906, 1994.
European Patent Office, European Search Report for EP 04380171.1, issued Jan. 25, 2005.
Zhu et al., J. Med. Chem., vol. 46, pp. 831-837, Jan. 21, 2003.
Alonso Luz Romero
Buschmann Helmut H.
Dordal Zueras Alberto
Jover Antoni Torrens
Lopez Monica Garcia
Davis Zinna N.
Laboratorios del Dr. Esteve S.A.
Morgan & Finnegan L.L.P.
LandOfFree
5-HT 7 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-HT 7 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-HT 7 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3810126